Pentavalent MenABCWY Vaccine Shows Evidence Of Broad Protection Against IMD In Young Adults, Adolescents, Study Finds

Infectious Disease Advisor (3/10, Nye) reports,” An investigational pentavalent meningococcal vaccine (MenABCWY) was found to be noninferior to the CRM197-glycoconjugate vaccine (MenACWY-CRM) for protection against invasive meningococcal disease (IMD) among MenACWY-primed adolescents and young adults.” Researchers concluded, “These findings provide further supporting evidence for the development of the MenABCWY vaccine for broad protection against IMD.” Findings from the study were published in Clinical Infectious Diseases.